Description
The debate identified major safety concerns with epigenetic modulators like DNMT3A inhibitors causing widespread chromatin changes. The specificity problem remains unsolved - whether memory-relevant epigenetic marks can be precisely modified without affecting tumor suppressor genes and other critical pathways.
Source: Debate session sess_SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 (Analysis: SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4)
Resolution criteria
Gap closes when: (1) A locus-specific epigenome editing approach (e.g., dCas9-DNMT3A or dCas9-TET1 with guide RNAs targeting memory-relevant loci) achieves >= 50% methylation change at target loci with < 5% off-target methylation changes genome-wide by WGBS; and (2) the intervention preserves mRNA expression of >= 95% of non-targeted genes (RNA-seq FDR > 0.1) in primary neurons over 7 days; and (3) behavioral outcomes (e.g., fear memory retention) are improved by >= 20% compared to scramble control in a validated mouse paradigm (n >= 15/group). Deliverable: WGBS off-target analysis, transcriptomics, and behavioral data with full statistical reporting.